Bio View

Bio View Equity Turnover

The Equity Turnover of Bio View (BIOV.TA) as of Oct 23, 2026 is 2.12. In the previous year, Equity Turnover was 1.12 — a change of 89.33% (higher).

Equity Turnover

2.12

YoY

89.33%

Last updated:

Equity Turnover of Bio View is 2025 2.12 . Equity Turnover of Bio View was 2024 1.12 . It decreases by 89.33% higher compared to the previous year.

The Bio View Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
1.11 ILS
Jan 1, 2019
1.43 ILS
Jan 1, 2020
1.04 ILS
Jan 1, 2021
1.12 ILS
Jan 1, 2022
1.03 ILS
Jan 1, 2023
1.27 ILS
Jan 1, 2024
1.12 ILS
Jan 1, 2025
2.12 ILS
The Bio View Equity Turnover history
YEAREquity TurnoverYoY
2.12+89.33%
1.12-12.19%
1.27+23.53%
1.03-8.25%
1.12+8.49%
1.04-27.81%
1.43+29.09%
1.11-6.11%
1.18-1.85%
1.21-19.73%
1.50-9.68%
1.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio View Stock analysis

What does Bio View do? BioView Ltd. generates revenue through the sale and servicing of its Duet automated cell diagnostic system, designed for use in cytology, cytogenetic, hematology, and pathology laboratories. The Duet system enables automated detection, classification, analysis, and counting of cells, offering unique capabilities in analyzing both cell morphology and genetic content simultaneously. Additional products include the ALLEGRO workstation for automated scanning of FISH probes without Brightfield scanning and the ACCORD workstation for semi-automated imaging of FISH in breast cancer (Her-2/Neu) analysis and FISH on tissue. These systems target medical professionals in cancer diagnosis, minimal-residual disease monitoring, prenatal and postnatal cytogenetic analyses, sperm cell studies, and rare-cell detection. The company's primary customers are laboratories specializing in cytology, cytogenetics, hematology, and pathology, including those focused on cancer diagnostics and genetic analysis. These institutions purchase the Duet system for routine diagnostic workflows and the ALLEGRO and ACCORD workstations for specialized applications such as FISH analysis in breast cancer and genetic studies. BioView Ltd. also provides ongoing servicing and support for its systems, contributing to recurring revenue streams. BioView Ltd. markets its products under the brand names Duet, ALLEGRO, and ACCORD, with the Duet system serving as the core offering for general cell analysis. The ALLEGRO and ACCORD workstations cater to niche applications in FISH-based diagnostics, particularly in oncology and genetic testing. The company's revenue is derived from direct sales of these systems to healthcare facilities and laboratories, with no mention of third-party partnerships or additional revenue streams beyond product sales and servicing. Bio View is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio View stock

Equity Turnover of Bio View is 2.12 in 2025.

Equity Turnover of Bio View changed from 1.12 to 2.12, representing a 89.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Bio View since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Bio View with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio View

All Key Metrics — Bio View